When considering a diagnosis of dermatomyositis-associated ILD, additional laboratory tests have been suggested to be of value. Anti-aminoacyl transfer RNA synthetase antibody (anti-Jo-1) defines a subgroup of patients with dermatomyositis who have an increased propensity for ILD. Such patients have a higher incidence of inflammatory polyarthritis, Raynaud phenomenon, and dilated vascular loops on nailfold capillaroscopy. The antibody is present in 20% of patients with dermatomyositis, and in 70% of patients with ILD. It is usually absent in patients with amyopathic dermatomyositis, even when ILD is present. Newer tests, such as KL-6 and anti-ADAM 10, serum surfactant protein D, and PL 12, are potential markers of dermatomyositis-ILD. It appears that KL-6 correlates with ILD severity and normalizes if ILD responds to therapy. None of these tests, however, has practical value for managing individual patients because of insufficient sensitivity and specificity. A detailed history and physical examination remain the best tests for detecting dermatomyositis in patients with ILD.